MIP and sanofi-aventis to develop separation polymers for biopharm
MIP Technologies is to collaborate with sanofi-aventis on the development of new molecularly imprinted polymers (MIPs) for the analysis of pharmacologically active peptides from plasma samples.
MIP Technologies is to collaborate with sanofi-aventis on the development of new molecularly imprinted polymers (MIPs) for the analysis of pharmacologically active peptides from plasma samples.
MIP Technologies will use a number of its patented molecular imprinting methods in the development of the polymers. The use of MIPs for selective recognition of peptides and proteins is a novel area that will open up the technology to numerous applications in the diagnostic, pharmaceutical and biopharmaceutical industries.
‘This collaboration with sanofi-aventis is both exciting and challenging,’ said Dr Anthony Rees, ceo at MIP Technologies. ‘We are looking to move into the development of peptide-selective MIPs which represents a valuable piece of the separations market and has applications in analytical, preparative and process scale separations.’
Sanofi-aventis will have exclusive access for use of the polymer in the analysis of proprietary peptide candidates, while MIP Technologies will retain the rights to use the polymers for other applications.